suPARnostic® TurbiLatex now CE-IVD approved for Roche Cobas c500/c700 series

Tue Feb 26 2019

ViroGates announces that the development and regulatory approval of the suPARnostic® TurbiLatex product for Roche Diagnostics cobas c500 and c700 series has been completed.

The suPARnostic® TurbiLatex product is a latex particle-enhanced turbidimetric immunoassay.

The Roche cobas c500 and c700 series are the market leading instruments for performing immunochemical analysis in the hospitals across Europe. According to Roche Diagnostics, more than 20,000 cobas instruments are installed worldwide, each with a throughput volume of up to 1,000 tests per hour.

suPARnostic® Turbilatex enables automatic handling of blood samples at clinical chemistry laboratories, and now all commercially relevant instruments within the Roche Diagnostic cobas series will be able to run suPARnostic® TurbiLatex tests.

Validation on other turbidimetric platforms will follow.

+800

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

suPAR is used in clinical routine in 38 hospitals

38 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling. This period covers October 1, 2021, until September 30, 2022.
Some hospital locations cannot be disclosed due to confidentiality.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates